We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Pharmacokinetics and Pharmacodynamics of a Single Acute Dose of a Hemp-derived Oral Product With a 1:1 Ratio of CBD:CBD-A

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05049733
Recruitment Status : Recruiting
First Posted : September 20, 2021
Last Update Posted : September 9, 2022
Sponsor:
Collaborator:
Cultivate Biologics
Information provided by (Responsible Party):
Johns Hopkins University

Brief Summary:
The purpose of this study is to examine the pharmacokinetics and pharmacodynamics of a hemp-derived oral product containing cannabidiol (CBD) and cannabidiolic acid (CBD-A) at a 1:1 ratio.

Condition or disease Intervention/treatment Phase
Cannabis Drug: CBD 1mg/Kg Drug: CBD 2mg/Kg Drug: CBD 4mg/Kg Drug: Placebo CBD Phase 1

Detailed Description:
The purpose of the present study is to examine the pharmacokinetics and pharmacodynamics of a novel hemp-derived oral cannabinoid product, at various doses, in healthy adults. The study will utilize a within-subjects, placebo-controlled, double-blind, ascending-dose design. Drug administration will be double blind (the participant and research staff will be unaware of the dose administered). Upon enrollment, participants will complete 4 dosing conditions (placebo, 1 mg/kg, 2 mg/kg, 4 mg/kg of cannabinoids). Each condition will consist of a single acute drug exposure, followed by an 8-hour period to evaluate acute pharmacodynamic and pharmacokinetic (PK) drug effects. Biological specimens (blood and urine) will be obtained throughout these 8 hours to characterize the pharmacokinetics of CBD, CBD-A, delta-9-Tetrahydrocannabinol (THC), and THC-A, as well as other relevant cannabinoids and metabolites. Pharmacodynamic assessments including subjective drug effects, cognitive performance testing, and vital signs will also be collected for 8 hours post-drug administration. For each of the two days after each experimental session, participants will be asked to return to the lab for brief visits (~20 min) to provide additional biospecimens (~24 and ~48 hrs after dosing) to allow for further PK analysis. These procedures will be completed 4 separate times by each participant (sessions will be separated by at least 1 week to allow for sufficient drug washout between doses).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: All participants will complete all dose conditions (study arms) in a randomized order
Masking: Double (Participant, Outcomes Assessor)
Masking Description: Double-blind (Participant, Outcomes Assessor), placebo controlled
Primary Purpose: Basic Science
Official Title: The Pharmacokinetics and Pharmacodynamics of a Single Acute Dose of a Hemp-derived Oral Product With a 1:1 Ratio of CBD:CBD-A
Actual Study Start Date : March 7, 2022
Estimated Primary Completion Date : December 31, 2022
Estimated Study Completion Date : December 31, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Arm 1
Participants will start with ingestion of soft gel tablets high in CBD and CBD-A, but low in THC and THC-A. The total amount of cannabinoids ingested will be 1 mg/kg and then switch to other doses after washout periods.
Drug: CBD 1mg/Kg
Participants will ingest soft gel tablets containing CBD 1mg/Kg

Drug: CBD 2mg/Kg
Participants will ingest soft gel tablets containing CBD 2mg/Kg

Drug: CBD 4mg/Kg
Participants will ingest soft gel tablets containing CBD 4mg/Kg

Drug: Placebo CBD
Participants will ingest soft gel tablets containing placebo for CBD

Experimental: Arm 2
Participants will start with ingestion of soft gel tablets high in CBD and CBD-A, but low in THC and THC-A. The total amount of cannabinoids ingested will be 2 mg/kg and then switch to other doses after washout periods.
Drug: CBD 1mg/Kg
Participants will ingest soft gel tablets containing CBD 1mg/Kg

Drug: CBD 2mg/Kg
Participants will ingest soft gel tablets containing CBD 2mg/Kg

Drug: CBD 4mg/Kg
Participants will ingest soft gel tablets containing CBD 4mg/Kg

Drug: Placebo CBD
Participants will ingest soft gel tablets containing placebo for CBD

Experimental: Arm 3
Participants will start with ingestion of soft gel tablets high in CBD and CBD-A, but low in THC and THC-A. The total amount of cannabinoids ingested will be 4 mg/kg and then switch to other doses after washout periods.
Drug: CBD 1mg/Kg
Participants will ingest soft gel tablets containing CBD 1mg/Kg

Drug: CBD 2mg/Kg
Participants will ingest soft gel tablets containing CBD 2mg/Kg

Drug: CBD 4mg/Kg
Participants will ingest soft gel tablets containing CBD 4mg/Kg

Drug: Placebo CBD
Participants will ingest soft gel tablets containing placebo for CBD

Placebo Comparator: Arm 4
Participants will begin with ingestion of placebo soft gel tablets that do not contain cannabinoids and then switch to other doses after washout periods.
Drug: CBD 1mg/Kg
Participants will ingest soft gel tablets containing CBD 1mg/Kg

Drug: CBD 2mg/Kg
Participants will ingest soft gel tablets containing CBD 2mg/Kg

Drug: CBD 4mg/Kg
Participants will ingest soft gel tablets containing CBD 4mg/Kg

Drug: Placebo CBD
Participants will ingest soft gel tablets containing placebo for CBD




Primary Outcome Measures :
  1. Pharmacokinetics - maximum concentration (CMax) for CBD [ Time Frame: 48 hrs ]
    Blood cannabinoid concentrations will be measured using quantitative liquid chromatography-tandem mass spectrometry (LC-MS-MS) analysis. The maximum concentration (Cmax) is determined as the highest concentration (in nanogram per milliliter, ng/mL) reached for each individual.

  2. Pharmacokinetics - maximum concentration (CMax) for CBD-A [ Time Frame: 48 hrs ]
    Blood cannabinoid concentrations will be measured using quantitative liquid chromatography-tandem mass spectrometry (LC-MS-MS) analysis. The maximum concentration (Cmax) is determined as the highest concentration (in nanogram per milliliter, ng/mL) reached for each individual.

  3. Pharmacokinetics - maximum concentration (CMax) for THC [ Time Frame: 48 hrs ]
    Blood cannabinoid concentrations will be measured using quantitative liquid chromatography-tandem mass spectrometry (LC-MS-MS) analysis. The maximum concentration (Cmax) is determined as the highest concentration (in nanogram per milliliter, ng/mL) reached for each individual.

  4. Pharmacokinetics - maximum concentration (CMax) for THC-A [ Time Frame: 48 hrs ]
    Blood cannabinoid concentrations will be measured using quantitative liquid chromatography-tandem mass spectrometry (LC-MS-MS) analysis. The maximum concentration (Cmax) is determined as the highest concentration (in nanogram per milliliter, ng/mL) reached for each individual.

  5. Pharmacokinetics - AUC for CBD [ Time Frame: 48 hrs ]
    Blood cannabinoid concentrations will be measured using quantitative liquid chromatography-tandem mass spectrometry (LC-MS-MS) analysis. The area under the curve (AUC) is calculated across all timepoints, minus the baseline.

  6. Pharmacokinetics - AUC for CBD-A [ Time Frame: 48 hrs ]
    Blood cannabinoid concentrations will be measured using quantitative liquid chromatography-tandem mass spectrometry (LC-MS-MS) analysis. The area under the curve (AUC) is calculated across all timepoints, minus the baseline.

  7. Pharmacokinetics - AUC for THC [ Time Frame: 48 hrs ]
    Blood cannabinoid concentrations will be measured using quantitative liquid chromatography-tandem mass spectrometry (LC-MS-MS) analysis. The area under the curve (AUC) is calculated across all timepoints, minus the baseline.

  8. Pharmacokinetics - AUC for THC-A [ Time Frame: 48 hrs ]
    Blood cannabinoid concentrations will be measured using quantitative liquid chromatography-tandem mass spectrometry (LC-MS-MS) analysis. The area under the curve (AUC) is calculated across all timepoints, minus the baseline.

  9. Pharmacokinetics - Tmax for CBD [ Time Frame: 48 hrs ]
    Blood cannabinoid concentrations will be measured using quantitative liquid chromatography-tandem mass spectrometry (LC-MS-MS) analysis. The Tmax, or time to reach maximum concentration, is the timepoint at which the Cmax is observed.

  10. Pharmacokinetics - Tmax for CBD-A [ Time Frame: 48 hrs ]
    Blood cannabinoid concentrations will be measured using quantitative liquid chromatography-tandem mass spectrometry (LC-MS-MS) analysis. The Tmax, or time to reach maximum concentration, is the timepoint at which the Cmax is observed.

  11. Pharmacokinetics - Tmax for THC [ Time Frame: 48 hrs ]
    Blood cannabinoid concentrations will be measured using quantitative liquid chromatography-tandem mass spectrometry (LC-MS-MS) analysis. The Tmax, or time to reach maximum concentration, is the timepoint at which the Cmax is observed.

  12. Pharmacokinetics - Tmax for THC-A [ Time Frame: 48 hrs ]
    Blood cannabinoid concentrations will be measured using quantitative liquid chromatography-tandem mass spectrometry (LC-MS-MS) analysis. The Tmax, or time to reach maximum concentration, is the timepoint at which the Cmax is observed.


Secondary Outcome Measures :
  1. Driving Under the Influence of Drugs (DRUID) application global impairment score [ Time Frame: 8 hrs ]
    Acute cognitive and behavioral impairment will be assessed with global impairment score(range 0-100) on the DRUID app (higher scores indicate greater impairment).

  2. Number of Correct Trials on Paced Auditory Serial Addition Task (PASAT) [ Time Frame: 8 hrs ]
    Computerized version of Paced Auditory Serial Addition Task will be administered to assess working memory performance. Will report the total correct trials out of 90 recorded (lower scores indicate worse performance).

  3. Number of Correct Trials on the Digit Symbol Substitution Task (DSST) [ Time Frame: 8 hrs ]
    Computerized version of Digit Symbol Substitution Task will be administered to assess psychomotor performance. Will report the total correct trials in 90 seconds (lower scores indicate worse performance).

  4. Distance from Central Stimulus on the Divided Attention Task (DAT) [ Time Frame: 8 hrs ]
    Computerized version of Divided Attention Task will be administered to assess divided attention. Will report the mean total distance from the central stimulus (in computer pixels) over the course of the task (higher scores indicate worse performance). Note that there is no defined upper limit to these scores.

  5. Feel Drug Effect as assessed by the Drug Effect Questionnaire (DEQ) [ Time Frame: 8 hrs ]
    The DEQ will be used to obtain subjective ratings of "feel drug effects". Score range from 0 (none) to 100 (extreme) using a 100mm line anchored with none/extreme designation.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Have provided written informed consent
  2. Be between the ages of 18 and 55
  3. Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests
  4. Test negative for recent cannabis use in urine at the screening visit and again upon admission for each experimental session
  5. Test negative for other drugs of abuse, including alcohol, at the screening visit and upon arrival for the experimental session
  6. Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at clinic admission
  7. Weigh between 110 lbs (50 kg) and 220 lbs (100 kg)
  8. Blood pressure at screening visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg
  9. Self-report prior experience using cannabis or CBD products, but no cannabis, cannabinoid, or hemp product use in the prior 30 days
  10. Have not donated blood in the prior 30 days
  11. For women of children bearing potential and men with female partners of child-bearing potential, must be willing to use an effective form of contraception during the study and for at least 30 days after the last drug administration session

Exclusion Criteria:

  1. Non-medical use of psychoactive drugs other than, nicotine, alcohol, or caffeine in the past 30 days
  2. History of or current evidence of significant medical or psychiatric illness judged by the investigator to put the participant at greater risk of experiencing an adverse event due to exposure or completion of other study procedures
  3. Use of an over-the-counter (OTC), systemic or topical drug(s), herbal supplement(s), or vitamin(s) within 14 days (or 5 half-lives for that specific drug) of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study results or the safety of the participant
  4. Use of a prescription medication (with the exception of birth control prescriptions) within 14 days (or 5 half-lives for that specific drug) of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the participant. This includes any medication metabolized via CYP2D6, CYP2C9, CYP2B10, or which induce/inhibit CYP3A4 enzymes.
  5. History of clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina)
  6. Enrolled in another clinical trial or have received any drug as part of a research study within 30 days prior to dosing
  7. Epilepsy or a history of seizures.
  8. Individuals with anemia for whom, in the opinion of the study team, participation would pose increased medical risk.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05049733


Contacts
Layout table for location contacts
Contact: Tory Spindle, PhD 410-550-0529 tspindle@jhmi.edu

Locations
Layout table for location information
United States, Maryland
Johns Hopkins Behavioral Pharmacology Research Unit Recruiting
Baltimore, Maryland, United States, 21224
Contact: Tory Spindle, PhD    410-550-0529    tspindle@jhmi.edu   
Sponsors and Collaborators
Johns Hopkins University
Cultivate Biologics
Investigators
Layout table for investigator information
Principal Investigator: Tory Spindle, PhD Johns Hopkins University
Layout table for additonal information
Responsible Party: Johns Hopkins University
ClinicalTrials.gov Identifier: NCT05049733    
Other Study ID Numbers: IRB00290381
First Posted: September 20, 2021    Key Record Dates
Last Update Posted: September 9, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Marijuana Abuse
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders